How to appeal a Humana pulmonary hypertension denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for pulmonary hypertension

Cited policy: Humana Uptravi (Selexipag) for PAH PA Criteria (Policy #coverage policy)

WHO Group 1 PAH RHC-confirmed, FC II–IV, on background ERA and/or PDE5i. Stepwise titration 200 mcg → individualized maximum tolerated dose (up to 1600 mcg BID). Prescribed by PH specialist. Reauth 6 mo on FC / 6MWD / hospitalization-free survival.

How Humana denies pulmonary hypertension — and how to counter it

Where Humana pushes back: 1) Must fail inhaled treprostinil first; 2) IV epoprostenol gold-standard for advanced disease; 3) FC II considered too mild for prostacyclin pathway.

Counter-arguments that hold up: Selexipag is an oral non-prostanoid prostacyclin RECEPTOR agonist (not an analog) — distinct MOA, FDA-approved Dec 21, 2015 based on GRIPHON Sitbon NEJM 2015;373(26):2522-2533 — event-driven Phase 3 n=1156, 40% reduction in composite morbidity-mortality vs placebo (HR 0.60, p<0.001). ESC/ERS 2022 + 7th World Symposium 2024 endorse selexipag for FC II–IV intermediate-risk patients on double therapy — adding selexipag is a recognized 4-strata escalation. Avoids inhalation device burden of inhaled treprostinil and central-line risk of IV epoprostenol. For FC II patients, GRIPHON FC II subgroup (n=540) showed consistent benefit — early prostacyclin escalation reduces clinical worsening.

What Humana typically denies for pulmonary hypertension

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For pulmonary hypertension, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the pulmonary hypertension treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Winrevair (sotatercept)
• Opsumit (macitentan)
• Letairis (ambrisentan)
• Tracleer (bosentan)
• Adcirca/Alyq (tadalafil)
• Revatio (sildenafil)

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.